Ribociclib Effective in Younger Breast Cancer Patients Too - Medscape /Link
Ribociclib Effective in Younger Breast Cancer Patients Too
SAN ANTONIO — The CDK4/6 inhibitor ribociclib (Kisqali, Novartis) dramatically improves progression-free survival (PFS) when added to endocrine therapy in ovarian-suppressed younger patients with hormone receptor-positive (HR+), human epidermal ...
For Breast Cancer Patients, Less Time on Hormonal Meds?
SABCS: I-SPY 3-year pCR results are powerful predictor for breast cancer survival
Acupuncture Dulls Pain from Drugs to Prevent Breast Ca Recurrence
Published on 08 Dec 2017 at 12:16AM